The Insulin Resistance Intervention after Stroke (IRIS) tested the hypothesis that pioglitazone, a glucose-lowering insulin-sensitizing drug used for the treatment of insulin resistance (a score of more than 3.0 on the HOMA-IR index), would reduce the rates of stroke and myocardial infarction after ischemic stroke or TIA in nondiabetic patients with insulin resistance, and achieved positive findings [5]. The gene discussed is INS; the disease is stroke disorder.